Drug intelligence / Profile preview

Sulfogaiacol + Pentoxyverine Citrate + Promethazine Hydrochloride Granules

Development stage
Unknown
Lead developer
Jiuhua Huayuan Group Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Sulfogaiacol + Pentoxyverine Citrate + Promethazine Hydrochloride Granules is a fixed-dose combination product developed and marketed by Anhui Jiuhua Huayuan Pharmaceutical for the symptomatic treatment of cough and upper respiratory tract symptoms. The formulation combines three active small molecules: sulfogaiacol, which acts as an expectorant to increase respiratory tract secretions and facilitate mucus clearance; pentoxyverine citrate, a non-opioid antitussive that suppresses the cough reflex through sigma-1 receptor agonism and muscarinic antagonism; and promethazine hydrochloride, a first-generation H1-antihistamine that reduces allergic symptoms and provides mild sedation. This synergistic combination is administered orally in granule form and is approved in China for typical symptomatic relief in respiratory conditions.

Other names
Sulfogaiacol + Pentoxyverine Citrate + Promethazine HydrochlorideSulfogaiacol Pentoxyverine Citrate and Promethazine Hydrochloride Granules
02

Targets

mAChR (Muscarinic acetylcholine receptors)SIGMAR1 (Sigma non-opioid intracellular receptor 1)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Sulfogaiacol + Pentoxyverine Citrate + Promethazine Hydrochloride Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sulfogaiacol + Pentoxyverine Citrate + Promethazine Hydrochloride Granules.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call